These resolutions include approval of the Merger Offers to Astra shareholders, the change of the Company's name to AstraZeneca PLC and the appointment of seven new directors, subject to and with effect from the Merger Offers becoming unconditional. Shareholders have also approved the redenomination of Zeneca Group PLC's share capital into US dollars.

The parties continue to expect the merger to be implemented in Q2 1999 as previously indicated.